- For Patients
- For Providers
hello@violetinfusions.com
2266 Orchard Lake Rd. Sylvan Lake, MI
(248) 971-1201
(248) 416-1499
TZIELD™ Infusion Therapy
TZIELD™ (teplizumab-mzwv) is a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D. This medication modifies T cell function to preserve beta cell function and is administered as a daily intravenous infusion for 14 consecutive days.
Meet our Infusion Specialists
Natali Craig
Product Designer
Phoenix Baker
Engineering Manager
Candice Wu
Backend Developer
Lana Steiner
Product Manager
For Provider
Simplify patient referrals and offer advanced treatment options with our infusion partnership program.
For Patient
There may be a better way to manage your condition – explore infusion therapy.
Cutting-edge infusion therapies and injections for patients with complex chronic conditions and rare diseases.
Navigations
Services
Contact Us
Resources
© 2024 violet health®: Infusion Care. All rights reserved.